Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Somewhat Bullish +50

Zimmer Biomet’s Mymobility Study: Fresh Clinical Data on a Digital Edge in Joint Replacement

🔬 Zimmer Biomet released updated clinical data from its Mymobility study evaluating a digital rehab platform paired with Apple Watch for hip and knee replacement patients.

📱 The app-based intervention provides education, exercise plans, and activity tracking to guide remote rehabilitation and reduce reliance on in-person physical therapy.

📊 Approximately 1,000 patients were randomized into the trial comparing Mymobility against standard physical therapy across multiple centers without blinding.

🎯 Key outcomes tracked include 30-day readmission rates, pain levels, function, balance, satisfaction, urgent care use, and overall safety over a 90-day period.

✅ The study has been marked as completed with primary and secondary outcomes recently entered into the ClinicalTrials.gov registry following submissions dating back to 2018.

🏥 Positive results showing lower readmissions or equivalent efficacy could encourage surgeon adoption and strengthen ZBH's pricing power for its bundled digital ecosystem.

💰 Successful validation supports a value-based care narrative by demonstrating potential cost savings from replacing some in-person visits with app-based remote monitoring.

⚔️ The data positions Zimmer Biomet against competitors like Stryker and Johnson & Johnson who are similarly investing in smart implants and digital health monitoring technologies.

📈 Strong clinical evidence could drive recurring revenue streams through software and data tools, moving beyond one-time implant sales to stickier customer relationships.

👀 Investors should monitor upcoming earnings calls for signs of major health systems integrating the Mymobility platform into standard joint replacement care pathways.

Bullish Signals
  • Zimmer Biomet completed its Mymobility clinical study with data showing app-based rehab is safe and effective compared to usual physical therapy after hip and knee replacement.
  • Positive outcomes on lower readmissions, pain reduction, and improved function could support higher surgeon adoption and stronger pricing power for ZBH's mymobility ecosystem.
  • Successful trial results would strengthen ZBH's narrative around value-based care and post-acute cost savings, boosting demand for implants bundled with digital services.
  • Completion of the study helps de-risk ZBH's spend on the mymobility platform while creating potential recurring revenue from software and data tools beyond one-time implant sales.
  • The Mymobility study positions Zimmer Biomet competitively against peers like Stryker and Johnson & Johnson in the connected orthopedics market.
Risk Factors
  • The study design includes no blinding, with both patients and doctors aware of which treatment group they are assigned, potentially introducing bias into the assessment of mymobility’s effectiveness compared to standard physical therapy.
Full Analysis
Zimmer Biomet Holdings (ZBH) announced that its prospective multicenter longitudinal cohort study titled "A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform" is complete and data have been analyzed. The trial evaluated whether Zimmer Biomet's mymobility app used with an Apple Watch could match or improve upon standard physical therapy following hip and knee replacement surgeries. Approximately 1,000 patients participated in a randomized head-to-head comparison between the mymobility platform and usual physical therapy across several centers. While the study is interventional with no blinding, allowing both patients and doctors to know the care type, it was designed as supportive care rather than drug testing, focusing primarily on reducing 30-day readmissions and measuring pain, function, balance, satisfaction, and urgent care use over a 90-day period. The study was first submitted on October 26, 2018, with the most recent update posted on March 20, 2026, signaling that clinical outcomes have been entered into the ClinicalTrials.gov system to validate ZBH's digital orthopedics efforts. Positive results from this completed study regarding lower readmissions or comparable effectiveness versus standard therapy could significantly benefit Zimmer Biomet by encouraging surgeon adoption and providing stronger pricing power for its mymobility ecosystem. If payers and hospitals confirm that app-based rehabilitation can safely replace certain in-person visits, demand may increase for ZBH implants bundled with digital services. This shift has the potential to create stickier customer relationships and generate recurring revenue from software and data tools beyond one-time implant sales, thereby aligning with the broader value-based care narrative focused on post-acute cost savings. In a competitive landscape where peers like Stryker and Johnson & Johnson are also investing in smart implants and digital monitoring, successful outcomes from this trial would help ZBH defend its share in connected orthopedics while potentially prompting competitors to accelerate their own digital offerings. Market reaction near term will hinge on how clearly ZBH connects these clinical results to reduced complications and fewer emergency visits. Investors are expected to monitor upcoming earnings calls and strategy updates for signs that major health systems plan to integrate mymobility into routine joint replacement pathways. The study supports the broader view that digital rehabilitation is a key growth driver in orthopedics, helping to de-risk ZBH's investment in the mymobility platform as it transitions from a tech concept to clinically validated solutions. By updating the trial status and posting outcomes on ClinicalTrials.gov, ZBH ensures the research remains current for investors tracking clinical evidence, reinforcing the validity of its digital transformation strategy within the medical device sector.